Pickering Interfaces, the leading supplier of modular signal switching and simulation solutions for use in electronic test and verification, has announced a new compact 12-slot LXI/USB modular chassis ...

The US Food and Drug Administration today announced it has approved Danish biotech firm Genmab’s Epkinly (epcoritamab-bysp) ...

ShipStation, the leading shipping and logistics solution, is helping merchants more confidently ship abroad from the United States. The company is simplifying international shipping through a new ...

Today, Benzinga's options scanner spotted 8 options trades for Biogen. This is not a typical pattern. The sentiment among ...

Unequal global access to inflammatory bowel disease (IBD) therapies creates profound health inequities. The increasing prevalence of IBD in Western countries, driven by high incidence rates and low ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...

SHANGHAI & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License ...

Despite the recent approval of targeted biologics that can significantly improve quality of life, Canadians living with ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with ...

Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care.